Phosphagenics (ASX: POH) has announced a development agreement with tesa Labtec GmbH, the German transdermal formulation specialists, to undertake the continued development of its transdermal TPM/Oxymorphone patch.
According to the company, the objective is to build on the work done to date and create a transdermal patch product with suitable characteristics for development through to commercialisation.
Once formulated, the patch will then be progressed towards an Investigational New Drug application with the US Food & Drug Administration, it said.
Phosphagenics previously worked with tesa to develop the TPM/Oxycodone patch, which is presently being investigated in a Phase 2 proof-of-concept study for Postherpetic Neuralgia.
According to Dr Ross Murdoch, CEO, “We assessed proposals from several potential partners before selecting tesa. We have confidence in their specialist skills and in their ability to complete the reformulation to a standard that will enable us, or a partner, to advance the program to commercialisation.
"Our previous work with TPM and Oxymorphone has already demonstrated that it is possible to achieve impressive transdermal delivery and plasma levels within the recognised therapeutic range. This collaboration is designed to take that accumulated know-how and build it into a patch with all the desirable characteristics necessary for successful commercialisation by ourselves or potential partners,” he added.